Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

Description

Chemotherapy Induced Thrombocytopenia Therapeutics Market is estimated to be valued at USD 1,688.0 Mn in 2025 and is expected to reach USD 2,375.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1,688.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.00%	2032 Value Projection:	USD 2,375.2 Mn

Thrombocytopenia is a condition in which blood platelets are low in person's body. Thrombocytes are colourless blood cells that help blood clot. Thrombocytopenia is common in cancer patients. The occurrence of chemotherapy-induced thrombocytopenia varies from person to person depending on the treatment used. Each chemotherapy agent differs in how it causes thrombocytopenia. Mostly chemotherapy-induced thrombocytopenia are caused by the gemcitabine-and platinum-based regimens used in chemotherapy. Alkylating agents affect stem cells, cyclophosphamide affects later megakaryocyte progenitors, bortezomib prevents platelet release from megakaryocytes, and some treatments promote platelet apoptosis. Thrombocytopenia can also occur with any infection or adverse drug reaction associated with cancer treatment. Chemotherapy-induced therapy can be particularly harmful, as it can delay chemotherapy, decrease the dose of chemotherapy drugs, increase medical expenses, and can cause induced bleeding.

Market Dynamics

The increasing number of cancer cases is expected to surge the number of chemotherapy procedures, and this is expected to drive the Euopean chemotherapy-induced thrombocytopenia therapeutics market. For instance, according to the World health Organization (WHO), over 3.7 million new cancer cases and 1.9 million death occur each year, and cancer represents the second most important cause of death and morbidity in 2012 in Europe, on a global scale, cancer accounted for 8.2 million deaths Currently, there are no approved treatments available for (chemotherapy-induced thrombocytopenia) CIT in the European Union.

However, growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period, owing to discontinuation of clinical trials due to failure of chemotherapy-induced thrombocytopenia therapeutics. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.

Key features of the study:

This report provides in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market compound annual growth rate (CAGR) for the forecast period: 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Amgen, Inc., Novartis AG., Pfizer Inc., LLC, Swedish Orphan Biovitrum AB., Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for dialysis market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration:
- Oral
- Injectable
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel:
- Hospital Pharmaciesa
- Retail Pharmacies
- Online Pharmacies
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Amgen, Inc.
- Novartis AG
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Jiangsu HengRui Medicine Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.

Product Code: CMI4332

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trend
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Acquisition and Collaboration Scenario

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - COVID-19 Impact Analysis

COVID-19 Epidemiology
Overall Impact on the Healthcare Sector
Total Impact of COVID-19 on the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market
Supply and Demand Analysis

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Heat Map Analysis
Company Profiles
- Amgen, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Swedish Orphan Biovitrum AB
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Jiangsu HengRui Medicine Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

10. Section

References
Research Methodology
About us and Sales Contact